- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT05246137
Zkouška fáze III k posouzení bezpečnosti a imunogenicity kandidátské posilovací vakcinace HIPRA proti COVID-19.
Fáze III, otevřená, jednoramenná, multicentrická, zkouška k posouzení bezpečnosti a imunogenicity posilovací vakcinace kandidátem rekombinantního proteinu RBD fúzního heterodimeru (PHH-1V) proti SARS-CoV-2 u dospělých očkovaných proti COVID -19.
This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adult subjects vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adults vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine at least 91 days before day 0. All the participants will receive a booster dose of the HIPRA's COVID-19 Vaccine and will be followed for 26 weeks or 52 weeks if they participate in the safety cohort, or the immunogenicity cohort, respectively.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
Milano
-
Milan, Milano, Itálie, 20162
- Hospital de Niguarda
-
-
-
-
BARCELONA
-
Badalona, BARCELONA, Španělsko, 08916
- Hospital Germans Trias I Pujol
-
Barcelona, BARCELONA, Španělsko, 08035
- Hospital Vall Hebron
-
-
Barcelona
-
Barcelona, Barcelona, Španělsko, 08023
- Hospital HM Delfos
-
Barcelona, Barcelona, Španělsko, 08023
- Hospital Quironsalud Barcelona
-
Mollet del Vallès, Barcelona, Španělsko, 08100
- Hospital de Mollet
-
-
Girona
-
Girona, Girona, Španělsko, 17007
- Hospital Universitari Dr. Josep Trueta
-
-
Madrid
-
Madrid, Madrid, Španělsko, 28046
- Hospital Universitario La Paz
-
Madrid, Madrid, Španělsko, 28007
- Hospital Gregorio Marañón
-
Madrid, Madrid, Španělsko, 28050
- Hospital HM Sanchinarro
-
Madrid, Madrid, Španělsko, 28660
- Hospital HM Montepríncipe
-
Madrid, Madrid, Španělsko, 28223
- Hospital Quironsalud Madrid
-
Meco, Madrid, Španělsko, 28805
- Hospital Principe de Asturias
-
Móstoles, Madrid, Španělsko, 28938
- Hospital HM Puerta del Sur
-
-
Málaga
-
Málaga, Málaga, Španělsko, 29010
- Hospital Regional Universitario de Málaga
-
-
Spain
-
Barcelona, Spain, Španělsko, 17170
- Hospital Clinic de Barcelona
-
-
VIZCAYA
-
Barakaldo, VIZCAYA, Španělsko, 48903
- Hospital de Cruces
-
-
Valencia
-
Valencia, Valencia, Španělsko, 46010
- Hospital Clínico de Valencia
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Male or female, ≥ 16 years old at Day 0.
- Willing to provide consent indicating that she or he understands the purpose and potential risks and is willing and able to participate in the study and comply with all the study requirements and procedures.
- Have a recognized primary vaccination scheme recognized by the authorities with Comirnaty, Spikevax, Vaxevria or Janssen at least 91 days and preferably a maximum of 240 days before Day 0.
- If having an underlying illnesses must be stable and well-controlled according to the investigator judgment.
- Participant is willing to avoid receiving live attenuated vaccines (licensed) within 4 weeks before screening or after receiving any study vaccine, or other not live vaccines (licensed) within 14 days before and after receiving any study vaccine.
- Participant agrees not to donate blood, blood products and bone marrow at least 3 months before and after vaccination.
- Female participant of childbearing potential must have a negative pregnancy test on the on Day 0 prior to vaccination.
- Female participant of childbearing potential must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (hormonal contraception: oral, injectable or transdermal patch, intrauterine device, vasectomized partner, sexual abstinence or condom).
- Male participants must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (vasectomized participants, condom, sexual abstinence).
- Male participants must refrain from donating sperm for at least 28 days after day 0.
Exclusion Criteria:
- History of anaphylaxis to any prior vaccine.
- Previous severe SARS-CoV-2 infections that required >24 hous of hospitalisation.
- Participant received or plans to receive live attenuated vaccines within 4 weeks before and after day 0; or other not live vaccines within 14 days before and after day 0.
- Pregnancy or breast-feeding at screening or Day 0 or willingness/intention to become pregnant during the study.
- Having a clinically significant acute illness or fever (temperature ≥38º C (100.4ºF)) at screening or within 48 hours prior to Day 0.
- Participant had a surgery requiring hospitalization before vaccination and he/she has not received the hospital discharge at day 0; or has a surgery requiring hospitalization planned within 12 weeks after study vaccine administration.
- Having any active malignancy even if under treatment except for non-melanoma skin cancer, uterine cervical carcinoma, anal carcinoma, localized prostate cancer.
- Having ongoing severe and non-stable psychiatric condition likely to affect participation in the study.
- Having problematic or risk use of substances including alcohol that can compromise the study follow-up.
- Having a bleeding disorder or has any condition that in the opinion of the investigator contraindicates intramuscular injections.
- Having abnormal function of the immune system, except stable clinical conditions like controlled HIV.
- Having clinically significant and unstable cardiovascular, respiratory, hepatic, neurological, gastrointestinal, renal, or any other medical disorder judged by the investigator within 3 months before screening.
- Chronic or recurrent administration of systemic immunosuppressant medication.
- Having received immunoglobulins and/or blood-derived products 12 weeks prior vaccination (Day 0) or expects to receive them during the study.
- Having received any immunotherapy (monoclonal antibodies, plasma) aimed to prevent or treat COVID-19 within 90 days before day 0.
- Participation in any research involving an investigational product (drug, biologic, device) within 12 weeks prior to vaccination and during the study.
- Participant has donated ≥ 450ml of blood products within 12 weeks before screening.
- Participant has any medical condition and/or finding that in the investigator opinion might increase participant risks, interfere with the study or impair interpretation of study data.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Experimental: COVID-19 Vaccine HIPRA 40 ug/dose
COVID-19 Vaccine HIPRA, where subjects will receive one intramuscular injection of COVID-19 vaccine developed by HIPRA |
Intramuscular injection of 0,5 ml with 40 ug of recombinant PHH-1V |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)
Časové okno: Day 7
|
Number, percentage, and characteristics of solicited local and systemic reactions through Day 7 after vaccination. |
Day 7
|
|
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) (AEs)
Časové okno: Day 28
|
Number, percentage, and characteristics of unsolicited local and systemic adverse events (AEs) through Day 28 after vaccination |
Day 28
|
|
Incidence of Serious Adverse Events (Safety and tolerability) (SAE)
Časové okno: Day 365
|
Number and percentage of serious adverse events (SAEs) through the end of the study. |
Day 365
|
|
Incidence of Special Interest Adverse Events (Safety and tolerability) (AESI).
Časové okno: Day 365
|
Number and percentage of adverse event of special interest (AESI) through the end of the study. |
Day 365
|
|
Incidence of Medically Attended Adverse Events (Safety and tolerability) (MAAEs)
Časové okno: Day 365
|
Number and percentage of medically attended adverse events (MAAE) related to study vaccine through the end of the study. |
Day 365
|
|
Incidence of Adverse Events in laboratory parameters (Safety and tolerability)
Časové okno: Day 365
|
Grade 3 and 4 changes from baseline in safety laboratory parameters at Days 14, 91 and 182 after vaccination. through the end of the study. |
Day 365
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Changes in the immunogenicity measured by pseudovirus neutralisation
Časové okno: Day 365
|
Neutralisation titre against Wuhan and Omicron strains, and any other relevant VOC in the epidemiologic moment, measured as inhibitory concentration 50 (IC50) by a pseudovirion-based neutralisation assay (PBNA) and reported as reciprocal concentration for each individual sample and geometric mean titre (GMT) for descriptive statistics analysis at Baseline and at Days 14, 91, 182 and 365. |
Day 365
|
|
Changes in the immunogenicity measured by pseudovirus neutralisation
Časové okno: Day 14
|
The geometric mean fold rise (GMFR) in neutralising antibody titre from baseline to Day 14. |
Day 14
|
|
Changes in the immunogenicity measured by means of total antibody against RBD
Časové okno: Day 365
|
Binding antibodies titre measured for each individual sample and GMT for descriptive statistics analysis at Baseline and Days 14, 91, 182 and 365. |
Day 365
|
|
Changes in the immunogenicity measured by means of total antibody against RBD.
Časové okno: Day 14
|
The geometric mean fold rise (GMFR) in binding antibody titre from baseline to Day 14. |
Day 14
|
|
Changes in the immunogenicity measured by means of total antibody against RBD
Časové okno: Day 14
|
The percentage of subjects that after the booster dose have a ≥4-fold change in binding antibodies titre from Baseline to Day 14. |
Day 14
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
To assess number of subjects with SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Časové okno: Day 365
|
Number and percentage of subjects with SARS-CoV-2 infections ≥14 days after PHH-1V booster according to COVID-19 infection criteria throughout the study duration. |
Day 365
|
|
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V. SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Časové okno: Day 365
|
Number and percentage of COVID-19 severe infections ≥14 days after PHH-1V booster and through the end of the study. |
Day 365
|
|
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V and hospital admissions SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Časové okno: Day 365
|
Number and percentage of hospital admissions associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study. |
Day 365
|
|
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V in ICU. SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Časové okno: Day 365
|
Number and percentage of intensive care unit (ICU) admissions associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study. |
Day 365
|
|
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V receiving noninvasive ventilation. SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Časové okno: Day 365
|
Number and percentage of noninvasive ventilation administration associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study. |
Day 365
|
|
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V causing death.
Časové okno: Day 365
|
Number and percentage of deaths associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study. |
Day 365
|
|
To evaluate T-cell mediated responses against the SARS-CoV-2 S glycoprotein at Baseline and Day 14 in subjects who have received two doses of Vaxzevria vaccine and PHH-1V as a booster..
Časové okno: Day 14
|
T-cell-mediated response to the SARS-CoV-2 S protein as measured by whole peripheral blood mononuclear cell (PBMC) stimulation by enzyme-linked immune absorbent spot (ELISpot) at Baseline and at Day 14. This analysis will be performed in 30 subjects. |
Day 14
|
|
To assess Th-1/Th-2 T-cell mediated responses against S protein at Baseline and Day 14 in subjects who have received two doses of Vaxzevria vaccine and PHH-1V as a booster.
Časové okno: Day 14
|
CD4+/CD8+ T-cell response to the SARS-CoV-2 S protein as measured by in vitro PBMC stimulation by cytokine staining assays at Baseline and at Day 14. This analysis will be performed in 30 subjects. |
Day 14
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: Teresa Prat, HIPRA SICENTIFIC S.L.U
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- HIPRA-HH-5
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .